Clinical Analysis of Thalidomide Combined with Erythropoietin and Iron Sucrose Injection in The Treatment of Malignant Tumors Complicated by Anemia of Chronic Disease
Department of Medical Oncology, Heilongjiang Provincial Hospital, Harbin 150036, Heilongjiang
Cancer Genetics and Epigenetics, 2019, Vol. 7, No. 6 doi: 10.5376/cge.2019.07.0006
Received: 05 Sep., 2019 Accepted: 20 Sep., 2019 Published: 30 Sep., 2019
© 2019 BioPublisher Publishing Platform
This is an open access article published under the terms of the Creative Commons Attribution License
, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Preferred citation for this article:
Wang L.R., Liu M.L., Zhao J., Wang W.X., Du Y., Sun S., Liu W., Dong X., Shi E.H., and Wang Y.H., 2019, Clinical analysis of thalidomide combined with erythropoietin and iron sucrose injection in the treatment of malignant tumors complicated by anemia of chronic disease, Cancer Genetics and Epigenetics, 7(6): 19-22 (doi: 10.5376/cge.2019.07.0006)
To evaluate the efficacy and safety of thalidomide combined with erythropoietin (EPO) and iron sucrose injection in the treatment of malignant tumors complicated by anemia of chronic disease (ACD). From January 2017 to January 2019, 60 patients with malignant tumors complicated by ACD were enrolled. Patients were randomly assigned to two treatment groups and one control group. The two treatment groups received continuous oral administration of thalidomide at 100/d.; EPO 150IU/kg, subcutaneous injection for 3 times a week; iron sucrose injection of 100mg was intravenously administrated once a week, EPO 150 IU/kg, subcutaneous injection for 3 times a week; iron sucrose injection of 100mg was intravenously administrated once a week; the control group received subcutaneous injection of EPO 150IU/kg for 3 times a week; polysaccharide iron complex of 150 mg was orally administrated once a day; after 8 weeks, reexamination of related indexes was performed, and the efficacy and adverse reactions were evaluated. HGB level was significantly higher in the thalidomide group than in the control group (P<0.05); moreover, the response rate was higher compared with the control group (P<0.05). Mild adverse reactions occurred in a few patients. Thalidomide combined with EPO and iron sucrose injection was more effective and safer in the treatment of malignant tumors complicated by ACD.
Thalidomide; erythropoietin; Iron sucrose; Anemia of chronic disease; Tumor
Cancer Genetics and Epigenetics
• Volume 7